Literature DB >> 12878211

Expression of erythropoietin receptor splice variants in human cancer.

Murat O Arcasoy1, Xiaohong Jiang, Zishan A Haroon.   

Abstract

Erythropoietin (EPO) regulates mammalian erythropoiesis by binding to its transmembrane receptor EPOR. Recent studies demonstrated functional EPOR expression in human cancer cells. Recombinant human EPO was reported to stimulate the proliferation of monolayer cultures of breast and renal carcinoma cells. Furthermore, administration of EPO-EPOR antagonists delayed the growth of uterine, ovarian, and mammary carcinoma cells in experimental animal models. In this study, we show EPOR transcript and protein expression in breast, colon, lung, ovary, and prostate cancer cells. Using reverse transcription-polymerase chain reaction, we isolated and characterized several novel cDNAs for EPOR splice variants expressed in cancer cells. Deduced amino acid sequences of the cDNAs revealed splice variants encoding soluble EPOR or membrane-bound EPOR peptides with intra-cytoplasmic, carboxy-terminal truncations. These findings indicate the expression of multiple EPOR isoforms in human cancer cells that may modulate the cellular effects of recombinant human EPO or EPO-EPOR antagonists.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12878211     DOI: 10.1016/s0006-291x(03)01303-2

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  27 in total

1.  The use of chemokine-releasing tissue engineering scaffolds in a model of inflammatory response-mediated melanoma cancer metastasis.

Authors:  Cheng-Yu Ko; Lanxiao Wu; Ashwin M Nair; Yi-Ting Tsai; Victor K Lin; Liping Tang
Journal:  Biomaterials       Date:  2011-10-22       Impact factor: 12.479

Review 2.  Cytokine receptor splice variants in hematologic diseases.

Authors:  Borwyn Wang; Hrishikesh Mehta
Journal:  Cytokine       Date:  2019-12-06       Impact factor: 3.861

Review 3.  Association between pharmaceutical support and basic science research on erythropoiesis-stimulating agents.

Authors:  Charles L Bennett; Stephen Y Lai; Michael Henke; Sara E Barnato; James O Armitage; Oliver Sartor
Journal:  Arch Intern Med       Date:  2010-09-13

Review 4.  Systemic VHL gene functions and the VHL disease.

Authors:  Hannah L Bader; Tien Hsu
Journal:  FEBS Lett       Date:  2012-04-25       Impact factor: 4.124

5.  Far-western blotting as a solution to the non-specificity of the anti-erythropoietin receptor antibody.

Authors:  Barbora Fecková; Patrícia Kimáková; Lenka Ilkovičová; Erika Szentpéteriová; Nataša Debeljak; Zuzana Solárová; Veronika Sačková; Martina Šemeláková; Mangesh Bhide; Peter Solár
Journal:  Oncol Lett       Date:  2016-06-24       Impact factor: 2.967

6.  Erythropoietin supports the survival of prostate cancer, but not growth and bone metastasis.

Authors:  Yusuke Shiozawa; Samantha McGee; Michael J Pienta; Natalie McGregor; Younghun Jung; Kenji Yumoto; Jingcheng Wang; Janice E Berry; Kenneth J Pienta; Russell S Taichman
Journal:  J Cell Biochem       Date:  2013-11       Impact factor: 4.429

Review 7.  Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data.

Authors:  Julia Bohlius; Kurt Schmidlin; Corinne Brillant; Guido Schwarzer; Sven Trelle; Jerome Seidenfeld; Marcel Zwahlen; Mike J Clarke; Olaf Weingart; Sabine Kluge; Margaret Piper; Maryann Napoli; Dirk Rades; David Steensma; Benjamin Djulbegovic; Martin F Fey; Isabelle Ray-Coquard; Volker Moebus; Gillian Thomas; Michael Untch; Martin Schumacher; Matthias Egger; Andreas Engert
Journal:  Cochrane Database Syst Rev       Date:  2009-07-08

8.  Survival and erythropoietin receptor protein in tumours from patients randomly treated with rhEPO for palliative care.

Authors:  Christina Lönnroth; Marie Svensson; Wenhua Wang; Ulla Körner; Peter Daneryd; Ola Nilsson; Kent Lundholm
Journal:  Med Oncol       Date:  2007-09-11       Impact factor: 3.064

9.  Pharmacologic inhibition of Jak2-Stat5 signaling By Jak2 inhibitor AZD1480 potently suppresses growth of both primary and castrate-resistant prostate cancer.

Authors:  Lei Gu; Zhiyong Liao; David T Hoang; Ayush Dagvadorj; Shilpa Gupta; Shauna Blackmon; Elyse Ellsworth; Pooja Talati; Benjamin Leiby; Michael Zinda; Costas D Lallas; Edouard J Trabulsi; Peter McCue; Leonard Gomella; Dennis Huszar; Marja T Nevalainen
Journal:  Clin Cancer Res       Date:  2013-08-13       Impact factor: 12.531

10.  Soluble erythropoietin receptor contributes to erythropoietin resistance in end-stage renal disease.

Authors:  Eliyahu V Khankin; Walter P Mutter; Hector Tamez; Hai-Tao Yuan; S Ananth Karumanchi; Ravi Thadhani
Journal:  PLoS One       Date:  2010-02-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.